Should biomarkers be used to design personalized medicine for the treatment of glioblastoma? (Q37797464)

23 August 2017

title

Should biomarkers be used to design personalized medicine for the treatment of glioblastoma? (English)

1 reference

23 August 2017

0 references

personalized medicine

1 reference

1

Michael Weller

1 reference

23 August 2017

2

Wolfgang Wick

1 reference

23 August 2017

5

Ghazaleh Tabatabai

1 reference

23 August 2017

3

Monika E Hegi

1 reference

23 August 2017

4

Roger Stupp

1 reference

23 August 2017

language of work or name

English

0 references

publication date

1 September 2010

1 reference

23 August 2017

1 reference

23 August 2017

volume

6

1 reference

23 August 2017

issue

9

1 reference

23 August 2017

page(s)

1407-1414

1 reference

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

MGMT gene silencing and benefit from temozolomide in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

An integrated genomic analysis of human glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and disappointments

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

MGMT promoter methylation in malignant gliomas: ready for personalized medicine?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

O(6)-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

IDH1 mutations in gliomas: when an enzyme loses its grip

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

IDH1 and IDH2 mutations in gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

Stem cells, cancer, and cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

Identification of human brain tumour initiating cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

Marker-independent identification of glioma-initiating cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

Glioma stem cells promote radioresistance by preferential activation of the DNA damage response

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

Allergy and inflammatory transcriptome is predominantly negatively correlated with CD133 expression in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

Limits of CD133 as a marker of glioma self-renewing cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

CD133 is a marker of bioenergetic stress in human glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

IFNalpha activates dormant haematopoietic stem cells in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

Methylated tumor-specific DNA as a plasma biomarker in patients with glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

p16 promoter methylation in the serum as a basis for the molecular diagnosis of gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

Quantitative detection of multiple gene promoter hypermethylation in tumor tissue, serum, and cerebrospinal fluid predicts prognosis of malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

Serum DNA can define tumor-specific genetic and epigenetic markers in gliomas of various grades

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

Serum YKL-40, a new prognostic biomarker in cancer patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

Emerging functions of microRNAs in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

Improving seroreactivity-based detection of glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

Elevated levels of MIC-1/GDF15 in the cerebrospinal fluid of patients are associated with glioblastoma and worse outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.113

21 January 2018

Identifiers

DOI

10.2217/FON.10.113

1 reference

23 August 2017

1 reference